The most prevalent grade 3–5 AEs associated with PD-1/L1 dual immunotherapy were hypertension (10.7%), proteinuria (6.8%), lipase level increased (5.1%), diarrhea (3.9%), fatigue (3.9%), rash maculopapular (3.2%), anemia (2.4%), peripheral neuropathy (2.2%) and neutropenia (2.2%). This evidence concerns the gene PDCD1 and peripheral neuropathy.